Clareo Health | Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ANRS, Emerging Infectious Diseases
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults (18 years-old or more)
Patient who received the first administration of Evusheld at 300 mg for less than 4 months and should receive a second dose, according to French recommendations OR Patient scheduled to receive or having received less than a month ago an injection of anti-SARS-CoV-2 monoclonal antibodies, as pre-exposure prophylaxis at 600 mg, according to the French SARS-CoV-2 RT recommendations
qPCR negative at baseline
SARS-CoV-2 RT-qPCR Negative at inclusion
Patients who remain seronegative after a complete COVID-19 vaccination schedule
Immunocompromised patients :
Hemopathy : chronic lymphoid leukemia, non hodgkin's lymphoma, HSCT Transplant recipient : kidney, liver, lungs Patients receiving anti CD20 or others immunosuppressor
Life expectancy \> 3 months
Social security affiliation
Lack of a legal protection measure
Signed informed consent
You may not be if
Participation to another clinical study
State medical aid
Ongoing or scheduled plasmapheresis or immunoadsorption
Pregnant / lactating woman
Patient whose isolation period is underway following contact with a confirmed case of SARS-CoV2 infection
Hypersensitivity to one of the active substances or to one of the excipients
